Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Express Scripts
UBS
Farmers Insurance
Fish and Richardson
Colorcon
Covington
McKesson
Daiichi Sankyo

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,108,866

« Back to Dashboard

Which drugs does patent 7,108,866 protect, and when does it expire?

Patent 7,108,866 protects CARDIZEM LA and is included in one NDA.

This patent has ten patent family members in eight countries.
Summary for Patent: 7,108,866
Title:Chronotherapeutic diltiazem formulations and the administration thereof
Abstract:A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a C.sub.max of Diltiazem in the blood at between about 10 hours and about 15 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans(i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and(ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.
Inventor(s): Albert; Kenneth Stephen (Mt. Kisco, NY), Maes; Paul Jose (Oakville, CA)
Assignee: Biovall Laboratories International SRL (St. Michael, BB)
Application Number:09/567,451
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation;

Drugs Protected by US Patent 7,108,866

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Valeant Intl CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-001 Feb 6, 2003 AB RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERTENSION AND ANGINA PECTORIS ➤ Sign Up
Valeant Intl CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-002 Feb 6, 2003 AB RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERTENSION AND ANGINA PECTORIS ➤ Sign Up
Valeant Intl CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-003 Feb 6, 2003 AB RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERTENSION AND ANGINA PECTORIS ➤ Sign Up
Valeant Intl CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-004 Feb 6, 2003 AB RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERTENSION AND ANGINA PECTORIS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,108,866

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Canada2292247Dec 10, 1999
Canada2307547May 04, 2000

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
US Army
Chubb
Cantor Fitzgerald
Daiichi Sankyo
Queensland Health
Baxter
UBS
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.